title: Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
authors.affiliation: Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Sham
authors.initials: S
authors.lastname: Mailankody
authors.affiliation: Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland3Center for Health Care Ethics, Oregon Health & Science University, Portland.
authors.forename: Vinay
authors.initials: V
authors.lastname: Prasad
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D003363:Cost Control; D017047:Cost Sharing; D016527:Drug Costs; D016345:Medicare Part B / Q000191:economics*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D055553:Prescription Drugs / Q000191:economics; D011787:Quality of Health Care; D012052:Reimbursement, Incentive; D020414:Risk Sharing, Financial; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D055553:Prescription Drugs